Loading…
Loading…
PPTDF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PPTDF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PPTDF and 80,000+ other tickers.
See exactly how PPTDF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PPTDF and 80,000+ other tickers.
PeptiDream Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative therapeutic solutions, including constrained peptides, small molecules, and peptide-drug conjugates. The company utilizes its exclusive Peptide Discovery Platform System (PDPS), an advanced drug discovery engine, to propel the development of its peptide-based product pipeline. PeptiDream also maintains a collaborative research initiative and an exclusive licensing agreement with Takeda Pharmaceutical Company Limited, specifically focused on developing peptide-drug conjugates for neuromuscular disorders. Founded in 2006, the company's operations are based in Kawasaki, Japan.
PeptiDream (OTCMKTS:PPTDF - Get Free Report) is anticipated to post its resultson Wednesday, August 12th. Analysts expect PeptiDream to post earnings of ($0.0196) per share and revenue of $34.8960 million for the quarter. PeptiDream Price Performance Shares of OTCMKTS PPTDF opened at $6.00 on Monday. The firm's 50-day moving average price is $6.19 and its
KAWASAKI, Japan--(BUSINESS WIRE)-- #DrugDelivery--The first patient has been dosed with 64Cu-PD-29875 in a first-in-human clinical study in patients with gastric cancer.
KAWASAKI, Japan--(BUSINESS WIRE)-- #Cancer--Completion of patient dosing in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T —a PET radiopharmaceutical targeting PSMA.
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan.
KAWASAKI, Japan--(BUSINESS WIRE)-- #AutoimmuneDisease--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced that Asahi Kasei Therapeutics (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Daisuke Okajima, hereinafter “Asahi Kasei Therapeutics”), its collaboration partner, has initiated a Phase 1 clinical trial*1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered throu.